A Message From Our Program Leader
Pulmonary Hypertension is a complex and often life-altering condition caused by elevated blood pressure in the arteries of the lungs. It can stem from a variety of causes, including connective tissue diseases and, increasingly, methamphetamine use.
Our patients range in age from teenagers to individuals more than 100 years old, and they often come to us with symptoms like fatigue, shortness of breath, weight gain, and exercise intolerance. These symptoms can be debilitating, but they don’t have to be.
At the HonorHealth Pulmonary Hypertension Program, our mission is to change the trajectory of this disease through research-driven care. We are deeply committed to advancing the science of Pulmonary Hypertension and translating discoveries into real-world treatments that restore quality of life.
About Our Program
At HonorHealth John C. Lincoln Medical Center, our Pulmonary Hypertension Program is advancing care through innovative clinical research led by Dr. Jonathan Moore as part of the Research Institute’s Multispecialty Research Division.
This is a new and rapidly growing program, built on a foundation of collaboration, cutting-edge science, and a commitment to improving patient outcomes. We are actively expanding our clinical trial portfolio and building partnerships to bring the latest therapies to our community. We are proud to lead a program that not only delivers compassionate care but also drives innovation. Our team is actively involved in Phase I–IV clinical trials.
“Our goals going forward are to continue to grow and develop the program,” says Dr. Moore. Plans are underway to apply for Center of Excellence designation for Pulmonary Hypertension treatment, a recognition that will reflect the high-quality care we provide and highlight the research driving the field forward.
Pulmonary Hypertension Facts and Figures
Pulmonary Hypertension affects 15–50 cases per 1 million people globally, with prevalence increasing to 10% among individuals over 65 years old. The average age of diagnosis is 45 years old for men, and 36 years old for women, though the condition is four times more common in women.
The 5-year survival rate for patients with idiopathic Pulmonary Arterial Hypertension (PAH) is about 60%, though outcomes vary based on disease subtype and access to treatment. Advances in targeted therapies have significantly improved survival over the past two decades.
Between 1990 and 2021, annual global PAH cases increased by 85.6%, from 23,301 to 43,251. Despite this rise, age-standardized death rates and disability-adjusted life years have decreased slightly, indicating progress in treatment and management.
